# EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC

> **NCT05150236** · PHASE2 · UNKNOWN · sponsor: **Australian and New Zealand Urogenital and Prostate Cancer Trials Group** · enrollment: 93 (actual)

## Conditions studied

- Prostatic Neoplasms
- Genital Neoplasms, Male
- Urogenital Neoplasms
- Prostate Cancer
- Neoplasms by Site
- Neoplasms
- Prostatic Disease

## Interventions

- **DRUG:** 177Lu-PSMA-617
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT05150236
- **Lead sponsor:** Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-29
- **Primary completion:** 2024-08-31
- **Final completion:** 2024-12
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2023-12-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05150236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05150236, "EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05150236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*